CV1

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Cv Check Ltd

🇦🇺 ASX

👑 Overview

📈 Performance

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

2
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Cv Check Ltd

📈 Performance

Price History

-85.00%

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.10

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in CV1

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

54 weeks

💵 Average investment amount

$2,752

Last time a customer invested in CV1

877 days
CV1 investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in CV1 also invest in...

Jcurve Solutions Ltd

JCS

JCurve Solutions Ltd. engages in the business of developing software applications and solutions for corporate and government industries. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2000-12-08. The firm is engaged in the sale, implementation and support of Enterprise Resource Planning (ERP) solutions, which consist of the exclusively licensed small business edition of Oracle NetSuite, JCurve ERP (in Australia and New Zealand), and the Oracle NetSuite mid-market and enterprise editions. Its segments include ANZ ERP, Asia ERP, TEMS and Quicta. ANZ ERP segment includes ERP cloud-based Business Management solutions and associated consulting services that are sold to Australian and New Zealand customers. Asia ERP segment includes ERP cloud-based Business Management solutions and associated consulting services, which are sold to Southeast Asian customers. TEMS segment develops and markets Telecommunications Expense Management Solutions (JTEL, Full Circle and Phoneware) that are sold to Australian customers. Quicta segment develops and sells service management and scheduling software.

🙌 Performance (5Yr p.a)

-0.74%

📊 Share price

$0.03 AUD

🤖 TECHNOLOGY

Find Out More

Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has a productive drug discovery engine and drug candidates in clinical trials. Its drug candidate, PXS-5505, is an orally taken drug that inhibits the lysyl oxidase family of enzymes. PXS-5505 is used for the treatment of the blood cancer myelofibrosis. PXS-5505 is also being investigated as a potential treatment for other cancers, such as liver and pancreatic cancer. Its other drugs in development include PXS-5382 (LOXL2 inhibitor), PXS-6302 (topical pan LOX inhibitor), PXS-4728 (SSAO inhibitor), PXS-4699 (dual SSAO/MAOB inhibitor) and PXS-5370 (dual SSAO/MPO inhibitor). Its drug candidates developed from the pipeline targets diseases where inflammatory and fibrotic processes play a significant role, which include pulmonary fibrosis, chronic kidney disease, NASH, Parkinson's disease and cardiac fibrosis.

🙌 Performance (5Yr p.a)

-17.96%

📊 Share price

$0.03 AUD

NULL PHARMACEUTICALS

Rex Minerals Ltd. engages in the exploration and development of mineral properties. The firm's projects include Hillside Project and Hog Ranch Project. The Hillside Project is located 165 kilometers (kms) from Adelaide and 12 km south of the Ardrossan township on the Yorke Peninsula, South Australia. The Hillside Project is an iron oxide copper gold (IOCG) deposit, under shallow cover, in the Gawler Craton, which collectively hosts the largest copper producing projects in Australia. The Hillside Project has a resource that contains approximately 1.9 Mt of copper (Cu) and 1.5 million ounces (Moz) of gold (Au) and is one of the most significant projects in Australia. The Hog Ranch Gold Property is located in Washoe County in north-west Nevada, approximately 45 km from the California border and 91 km from the Oregon border. The Hog Ranch Gold Property has a Joint Ore Reserve Committee (JORC) compliant Mineral Resource of approximately 2.2 Moz gold.

🙌 Performance (5Yr p.a)

94.81%

📊 Share price

$0.47 AUD

⛏️ MINING

Kinatico Ltd. engages in the provision of screening and verification services. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-09-08. The Company’s solutions comprise pre-employment screening, verification services and workforce compliance management internationally. The company provides real-time workforce compliance management via its core software-as-a-service RegTech solution Cited. By combining certifications and compliance data with business policy and legislative requirements, Cited enables scalable compliance monitoring spanning pre-employment to real-time requirements related to geo-location, roles and tasks applicable across a range of industries. The company also provides a range of pre-employment checks via its CVCheck solution. This is delivered via its technology platform, which include employment screening and verification offering. Its OnCite is a native mobile application available in iOS and Android, that allows workers to manage their own compliance daily, control their own credentials, and share that information.

🙌 Performance (5Yr p.a)

-1.33%

📊 Share price

$0.14 AUD

🤖 TECHNOLOGY

Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

🙌 Performance (5Yr p.a)

-11.45%

📊 Share price

$0.06 AUD

🕊️ SOCIALLY AWARE

📦 LOGISTICS